A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

Demographical characteristics

Gender Age at time of 1L initiation Race Region indicator (i.e., US vs. ex-US)

Time frame: From Time of Initiation of First-line (1L) Immuno-oncology (IO) combination therapy to death (up to 60 months)

Date of mRCC diagnosis

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Prior nephrectomy status

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Date of nephrectomy (if applicable)

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Tumor characteristics

Histology type (i.e., clear cell vs. non-clear cell RCC) Number of metastatic sites (e.g., 1 site or more than 1 site) Site of metastases (e.g., brain, bone, lung)

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

IMDC risk score

Assessed on index date and at initiation of each LOT

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Number of lines of therapy received by each patient

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Treatment agents received at each line of therapy

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Duration of each line of therapy

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Time from discontinuation of previous line of therapy to initiation of subsequent line of therapy

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Reason for discontinuation for each line of therapy

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Time to treatment discontinuation (TTD)

Defined as the time from treatment initiation to discontinuation of each therapy due to any reason including progression, death, or toxicity

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Time to next treatment (TTNT)

Defined as time from the initiation of 1L treatment to initiation of subsequent therapy or death

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Physician-assessed best response

Overall best response rate (complete or partial) Stable disease Progressive disease

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)

Overall survival

Defined as the time between initiation of 1L IO combination therapy to death

Time frame: From Time of Initiation of 1L IO combination therapy to death (up to 60 months)